Stock Report

Download full stock data and analysis for free Last Updated: 12-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Navidea Biopharmaceuticals (NAVB) Key Ratios

Stock Card factsheet share-fund-plan-icon

$0.00

up-down-arrow $-0.04 (-99.76%)

As on 18-Dec-2025 09:30EDT

Market cap

info icon

$0 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

8.2

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -99.05 -73.72 -75.44
EBIT 12.54 61.99 40.99 4.98 6.95
Net Profit -137.39 60.49 92.30 22.99 14.06
EPS -118.15 87.78 90.01 23.83 14.59
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-22Dec-21
EBIT-Margin info -8,258.33-13,873.90-1,476,651.48-21,402.08-2,202.30
Net Margin info -1,176.33-8,521.14-193,849.18----
Return on equity info 1,878.34-2,653.21--403.05-1,940.52
Return on Capital info -359.54-548.04--642.67-712.07
Return on Assets info -218.04-193.27-8.34-312.53-162.90
Debt to Equity (x) info ----0.00-0.29-7.03

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
--
642.67
-712.07
-1,009.21
-1,457.20
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

--

--

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
--
403.05
-1,940.52
7,172.49
-18,655.01
Peer Median
-40.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-8.34

Higher than Peers by 22.91

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
-8.34
-312.53
-162.90
-178.69
-196.16
Peer Median
-31.24
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-1,476,651.48

Lower than Peers by 1,476,568.88

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
-1,476,651.48
-21,402.08
-2,202.30
-1,170.60
-41,184.60
Peer Median
-82.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-193,849.18

Lower than Peers by 193,757.88

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
-193,849.18
-26,221.65
-2,207.08
-1,176.33
-24,711.69
Peer Median
-91.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

-1.79

Lower than Peers by 1.79

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
-1.79
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-99.05

Lower than Peers by 153.09

Year on year growth in net sales

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
-99.05
-0.88
-0.42
33.38
-0.92
Peer Median
54.03
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

40.99

Higher than Peers by 42.01

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
40.99
-20.04
-9.28
2.29
0.32
Peer Median
-1.02
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

92.30

Higher than Peers by 99.83

Year on year growth in profit after tax

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
92.30
-46.75
-10.25
2.79
32.13
Peer Median
-7.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

90.01

Higher than Peers by 75.78

Year on year growth in earnings per share

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
90.01
-0.37
0.02
0.33
0.65
Peer Median
14.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

79.59

Higher than Peers by 89.72

Year on year growth in book value per share

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
79.59
--
--
--
--
Peer Median
-10.13
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
--
-0.29
-7.03
1.02
-0.66
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

-0.38

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
-0.38
-0.07
-6.84
0.79
-0.50
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

0.56

Lower than Peers by 5.25

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
0.56
0.32
1.02
1.38
0.76
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.51

Lower than Peers by 5.19

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
0.51
0.28
0.99
1.35
1.00
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-6.02

Lower than Peers by 3.94

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
-6.02
-12.79
-1,840.20
-944.22
-433.51
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

5,060.66

Higher than Peers by 5,041.64

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
5,060.66
0.96
17.50
326.48
3,386.20
Peer Median
19.01
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.00

Lower than Peers by 0.06

Sales / Average Total Assets

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
0.00
0.01
0.07
0.15
0.00
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
--
260.43
1,058.38
776.13
6,329.17
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
--
571.24
294.79
-127,478.70
-24,689.79
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
--
3,499.36
2,372.46
396,231.08
42,096.25
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
--
-2,667.70
-1,019.30
-522,933.65
-60,456.88
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
--
-0.39
-2.57
-5.40
-2.10
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

8.16

Higher than Peers by 2.84

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
8.16
-0.81
-283.06
43.67
-14.29
Peer Median
5.33
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-0.54

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
-0.54
-0.52
-2.32
-5.27
-2.13
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

0

Lower than Peers by 142

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-22
Dec-21
Dec-20
Dec-19
Navidea Biopharmaceuticals (NAVB)
0
--
--
--
--
Peer Median
142
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...